U.S., Sept. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07818421) titled 'Intratumoral Microbiota and Immune Microenvironment in Prostate Cancer' on Sept. 08.
Brief Summary: Prostate cancer is a common malignancy in men, with rising incidence worldwide. Current clinical risk assessment tools-including PSA, Gleason score/ISUP grade, pathological stage, margin status, perineural invasion, and postoperative PSA kinetics-cannot fully explain the marked heterogeneity in disease progression, recurrence, and treatment response, highlighting the need for novel microenvironment-based biomarkers. Emerging evidence has identified intratumoral microbiota as a component of the tumor microenvironment in various solid ...